Preclinical News and Research

RSS
GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera’s G-115 anti-cancer drug awarded US patent

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris broadens patent protection for recombinant human interleukin-7

Isogenica, Phylogica partner in Phylomer peptide development

Isogenica, Phylogica partner in Phylomer peptide development

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Study evaluates hepatocyte transplantation as an alternative to liver transplantation

Study evaluates hepatocyte transplantation as an alternative to liver transplantation

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

YM BioSciences-Cytopia merger complete

YM BioSciences-Cytopia merger complete

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Global market for oncology drugs is forecast to reach $80 billion by 2050

Global market for oncology drugs is forecast to reach $80 billion by 2050

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals acquires Metabasis Therapeutics

NIDA supports Omeros' Addiction program

NIDA supports Omeros' Addiction program

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene reports total revenue of $758M for fourth-quarter of 2009

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.